Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients

被引:42
作者
Allinson, Katherine [1 ,2 ,3 ]
Kolve, Hedwig [1 ,2 ,4 ]
Gumbinger, Hans G. [5 ]
Vormoor, H. Josef [1 ,2 ]
Ehlert, Karoline [1 ,2 ]
Groll, Andreas H. [1 ,2 ]
机构
[1] Childrens Univ Hosp, Ctr Bone Marrow Transplant, Infect Dis Res Program, D-48129 Munster, Germany
[2] Childrens Univ Hosp, Dept Paediat Haematol Oncol, D-48129 Munster, Germany
[3] Cardiff Univ, Sch Med, Cardiff, S Glam, Wales
[4] Univ Hosp Munster, Dept Pharm, Munster, Germany
[5] Univ Hosp Munster, Dept Pharmacol & Toxicol, Munster, Germany
关键词
mycoses; stem cell transplantation; voriconazole; amphotericin B;
D O I
10.1093/jac/dkm521
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: Presumed or proven invasive pulmonary aspergillosis (IPA) is an important cause of infectious morbidity in patients with acute leukaemia. Although prior IPA is not a contraindication for subsequent allogeneic haematopoietic stem cell transplantation (HSCT), its management during granulocytopenia and immunosuppression remains challenging. Patients and methods: In the absence of an evidence-based approach, 11 adolescents (11-18 years) with acute leukaemia and a history of antecedent possible (4) or probable (7) IPA received liposomal amphotericin B (LAMB; 1 mg/kg once a day) from the start of the conditioning regimen until engraftment and ability to take oral medication, followed by oral voriconazole (200 mg twice a day) until the end of the at-risk period. Nine patients had a good partial response (> 50% reduction in pulmonary infiltrates) and two had a complete response prior to HSCT. Results: The median duration of intravenous treatment with LAMB was 30 days (range, 19-36), followed by a median of 152 days (range, 19-210) of oral voriconazole. LAMB was discontinued early in one patient and voriconazole was transiently or permanently discontinued due to adverse events/new contraindications in two and two patients, respectively. At +180 days post-transplant, eight patients were alive, six with complete, and one each with near complete and ongoing resolution of pulmonary infiltrates; all but one were in continuing haematological remission. Three patients had succumbed either to recurrent leukaemia (two) or refractory graft failure (one); whereas one of these patients had maintained a complete response, two died with secondary possible (one) or probable (one) IPA. Both patients had discontinued voriconazole early and developed IPA in lung areas involved during the primary episode. Conclusions: This prospective paediatric series supports the notion that secondary antifungal prophylaxis for possible or probable IPA can be safely achieved in allogeneic HSCT. In the absence of chronic graft-versus-host disease, breakthrough infection appeared to be associated with recurrent leukaemia/graft failure and shorter duration of post-engraftment prophylaxis.
引用
收藏
页码:734 / 742
页数:9
相关论文
共 46 条
[41]  
*US FDA, COMM TERM CRIT ADV E
[42]   Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children [J].
Walsh, TJ ;
Lutsar, I ;
Driscoll, T ;
Dupont, B ;
Roden, M ;
Ghahramani, P ;
Hodges, M ;
Groll, AH ;
Perfect, JR .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (03) :240-248
[43]   Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration [J].
Walsh, TJ ;
Karlsson, MO ;
Driscoll, T ;
Arguedas, AG ;
Adamson, P ;
Saez-Llorens, X ;
Vora, AJ ;
Arrieta, AC ;
Blumer, J ;
Lutsar, I ;
Milligan, P ;
Wood, N .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2166-2172
[44]  
Walsh TJ, 46 INT C ANT AG CHEM
[45]   Prolonged survival after invasive aspergillosis: A single-institution review of 11 cases [J].
Wright, JA ;
Bradfield, SM ;
Park, JR ;
Hawkins, DS .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (04) :286-291
[46]   Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000 [J].
Zaoutis, TE ;
Heydon, K ;
Chu, JH ;
Walsh, TJ ;
Steinbach, WJ .
PEDIATRICS, 2006, 117 (04) :E711-E716